AREVA PHARMA
Live / Allowed — Third extension granted (statement of use) (as of 12 Oct 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Mar 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98466090
- Mark type
- Word mark
- Filed
- 25 Mar 2024
- Published for opposition
- 24 Dec 2024
- Attorney of record
- Michael S. Hargis
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension; pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension, in the form of oncology injectables and oral solids
Owner
- Areva Pharmaceuticals Inc., Georgetown, IN, US
- Areva Pharmaceuticals Inc., Georgetown, IN, US
Board proceedings on this mark
- Extension of Time to Oppose No. 98466090 — Haleon UK IP Limited v. Areva Pharmaceuticals Inc., filed 23 Jan 2025 (Terminated)
Prosecution history
- 13 Oct 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Oct 2026 — SOU EXTENSION 3 GRANTED
- 12 Oct 2026 — SOU EXTENSION 3 FILED
- 12 Oct 2026 — SOU TEAS EXTENSION RECEIVED
- 11 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Apr 2026 — SOU EXTENSION 2 GRANTED
- 11 Apr 2026 — SOU EXTENSION 2 FILED
- 11 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Oct 2025 — SOU EXTENSION 1 GRANTED
- 14 Oct 2025 — SOU EXTENSION 1 FILED
- 14 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 05 May 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 05 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED